2 completed. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 2 |
Follow David Bajor, MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer CPI 613, Oxaliplatin, Irinotecan - Pancreatic Cancer | Phase 1 / Phase 2 | Completed | David Bajor, MD | 49 | 2018-12-07 | 2025-01-23 |
| CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer CB-839, Capecitabine - Colorectal Cancer, Colon Cancer | Phase 1 / Phase 2 | Completed | David Bajor, MD | 50 | 2016-09-12 | 2024-12-19 |
Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Pancreatic Neoplasms (1) · Rectal Neoplasms (1)
CB-839 (1) · Capecitabine (1) · Fluorouracil (1) · Irinotecan (1) · Leucovorin (1) · Oxaliplatin (1) · devimistat (1)
United States (2)